预测腔面型膀胱癌病理升级的基因组分类器
本研究针对临床分期cT1-T2N0M0的腔面型高级别膀胱尿路上皮癌,开发了一个单样本基因组分类器(luminal up staging classifier),用于预测根治性膀胱切除术时病理升级为非器官局限性疾病。在训练集75例、测试集25例中,分类器预测34例升级中的32例(AUC 0.96),pN+检测敏感性95%,预测升级者生存更差(p=0.001)。
要点
- 腔面型cT1-T2膀胱癌中34%根治性膀胱切除时升级为非器官局限性疾病。
- 基因组分类器预测升级AUC 0.96,pN+敏感性95%。
- 预测升级者总生存显著更差(p=0.001),可辅助治疗决策。
核心结论
- 开发了腔面型升级分类器,可区分cT1-T2N0M0腔面型尿路上皮癌中根治性膀胱切除时高升级风险及高死亡风险亚群。
研究设计与样本
- 回顾性分析经尿道切除的高级别cT1-T2N0M0膀胱尿路上皮癌标本,均为腔面亚型(Seiler 2017),随机分为训练集75例和测试集25例。
- 使用lasso/ridge惩罚逻辑回归开发单样本腔面升级分类器,所有患者接受根治性膀胱切除且未行新辅助化疗,主要终点为升级为非器官局限性疾病。
- 另用根治性膀胱切除队列和铂类新辅助化疗队列评估分类器。
主要发现
- 腔面型病例中34%升级为非器官局限性疾病。
- 分类器在34例升级中预测32例,假阳性6例,AUC 0.96。
- 检测腔面型pN+疾病的敏感性为95%(20/21)。
- 预测为非器官局限的腔面型肿瘤患者生存差于器官局限者(p=0.001)。
- 多变量分析中,校正经尿道切除时可用临床变量后,分类器是全因生存的显著预测因子;在侵袭性腔面型TCGA病例(n=83)中亦预测总生存(p=0.043)。
临床怎么用
- 对于cT1-T2N0M0腔面型高级别膀胱尿路上皮癌,可考虑用该分类器识别高升级风险患者,辅助是否保留新辅助化疗等治疗决策。
局限性
- 需在独立大样本队列中验证该模型,以确定腔面型肿瘤分子分层如何指导治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Urothelial carcinoma of the luminal molecular subtype is associated with lower rates of pathological up staging from clinical stage T1-T2 to nonorgan confined (pT3 or greater and/or pN+) disease at radical cystectomy. However, approximately a third of luminal urothelial carcinoma cases were up staged to nonorgan confined disease, and these may be under treated if neoadjuvant chemotherapy is withheld. In this study we trained a genomic classifier to predict luminal nonorgan confined disease in patients diagnosed with clinically organ confined (cT1/T2) disease. MATERIALS AND METHODS: Specimens from transurethral resected high grade cT1-T2N0M0 urothelial carcinoma of the bladder that belonged to the luminal subtype (Seiler 2017) were randomly split into training (75) and testing (25) sets for the development of a single sample luminal up staging classifier using lasso/ridge-penalized logistic regression. All patients underwent radical cystectomy without neoadjuvant chemotherapy and the primary end point was up staging to nonorgan confined disease. A radical cystectomy cohort and a platinum treated neoadjuvant chemotherapy cohort were used to evaluate the luminal up staging classifier. RESULTS: Up staging to nonorgan confined disease occurred in 34% of luminal cases. The luminal up staging classifier predicted up staging in 32 of 34 cases, with 6 false-positives (AUC 0.96). The sensitivity for detection of luminal pN+ disease was 95% (20 of 21). Patients with predicted nonorgan confined luminal tumors had worse survival than those with organ confined luminal tumors (p=0.001). On multivariable analysis the luminal up staging classifier was a significant predictor of overall survival after adjusting for clinical variables available at transurethral resection. The luminal up staging classifier also predicted overall survival for aggressive luminal TCGA (The Cancer Genome Atlas) cases (n=83, p=0.043). In the neoadjuvant chemotherapy cohort the luminal up staging classifier predicted 9 up staging cases, all of which had excellent prognosis. CONCLUSIONS: A luminal up staging classifier was developed that distinguishes a subset of cT1-T2N0M0 luminal urothelial carcinoma cases at high risk for up staging to nonorgan confined disease at radical cystectomy and of death. Validation of this model in an independent, large patient cohort is necessary to determine how molecular stratification of luminal tumors could be used to guide treatment of these patients.
引用
- de Jong JJ, Liu Y, Boorjian SA, et al. A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging. J Urol. 2020. PMID: 32074006. doi:10.1097/JU.0000000000000798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。